Cover Image

Healthcare costs in patients with metastatic lung cancer receiving chemotherapy

<p>Abstract</p> <p>Background</p> <p>To characterize healthcare resource utilization and costs in patients with metastatic lung cancer receiving chemotherapy in the US.</p> <p>Methods</p> <p>Using data from a large private multi-payer health insu...

Full description

Saved in:

Bibliographic Details
Main Authors:	Vera-Llonch Montserrat (Author), Weycker Derek (Author), Glass Andrew (Author), Gao Sue (Author), Borker Rohit (Author), Barber Beth (Author), Oster Gerry (Author)
Format:	Book
Published:	BMC, 2011-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis
by: Xueyan Liang, et al.
Published: (2023)

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
by: Xia Luo, et al.
Published: (2022)

US healthcare costs attributable to type A and type B influenza
by: Songkai Yan, et al.
Published: (2017)

Metastatic lung malignancy to mandibular gingiva
by: Moharil Rohit, et al.
Published: (2010)

Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer
by: Zhiwei Zheng, et al.
Published: (2022)

Costs by Site of Service for Commercially-Insured Patients with Metastatic Pancreatic Cancer Receiving Guideline-Recommended Chemotherapy: Comparing Community Oncology and Hospital Outpatient Settings
by: Tomicki S, et al.
Published: (2022)

First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
by: Wenjie Liu, et al.
Published: (2023)

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024)

Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
by: Xiaoyan Liu, et al.
Published: (2021)

Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases
by: Weycker Derek, et al.
Published: (2013)

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
by: Zhengda Pei, et al.
Published: (2023)

Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector's and societal perspectives
by: Yena Gan, et al.
Published: (2024)

Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024)

Chemotherapy administration checklist for patients receiving chemotherapy: Development and validation
by: Gitika Miglani, et al.
Published: (2022)

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
by: Jiao Xie, et al.
Published: (2023)

Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China
by: Wei Li, et al.
Published: (2022)

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019)

Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China
by: Zuojuan Xiang, et al.
Published: (2024)

Retreatment of chemotherapy-resistant metastatic choriocarcinoma with immunotherapy
by: Adriana J. Wong, et al.
Published: (2022)

The prognostic role of markers of systemic inflammation in patients with metastatic lung cancer receiving immunotherapy: A comprehensive review of the literature
by: Tanya Zlatanova, et al.
Published: (2024)

FATIGUE IN CANCER PATIENTS RECEIVING CHEMOTHERAPY
by: M. Farajollahi, et al.
Published: (2004)

Ototoxicity in children receiving cisplatin chemotherapy
by: Hee Jin Jang, et al.
Published: (2010)

Resource utilization and costs before and after total joint arthroplasty
by: Bozic Kevin J, et al.
Published: (2012)

Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
by: Xiaoyan Liu, et al.
Published: (2022)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
by: Hongfu Cai, et al.
Published: (2021)

Unsupported off-label chemotherapy in metastatic colon cancer
by: de Souza Jonas A, et al.
Published: (2012)

Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis
by: Gengwei Huo, et al.
Published: (2023)

Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer
by: Thérèse H Franco, et al.
Published: (2008)

Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
by: Zhou C, et al.
Published: (2023)

Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
by: Yanhong Liu, et al.
Published: (2024)

Metastatic Lung Adenocarcinoma to the Oral Cavity
by: Mohd Naqiuddin Mohd Najib, et al.
Published: (2023)

Surgical treatment of metastatic diseases to the lung
by: Jarosław Religioni, et al.
Published: (2020)

Hemangioblastoma in the Lung: Metastatic or Primary Lesions?
by: Li Lu, et al.
Published: (2014)

Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer
by: Maojin You, et al.
Published: (2022)

Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China
by: Xiaoyu Zhang, et al.
Published: (2024)

Maintenance therapy with oral etoposide following first-line docetaxel-cisplatin chemotherapy in metastatic non-small cell lung cancer patients
by: Meiyu Fang, et al.
Published: (2012)

Sequential Metastatic Breast Cancer Chemotherapy:Should the Median be the Message?
by: Su Yon eJung, et al.
Published: (2013)

From chemotherapy to oncoviruses - modern methods of treatment in metastatic melanoma
by: Hanna H. Drobek, et al.
Published: (2017)

Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatinand irinotecan-based chemotherapy and biologics in the US
by: Victoria Federico Paly, et al.
Published: (2024)

Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy
by: Zheng Y, et al.
Published: (2021)